Business & price at a glance
Financial reporting gap. Latest stored quarter: Dec 2025; annual: Mar 2025. Check newer filings before drawing conclusions. View sources
The model estimate is 58.0% below the stored share price. This gap depends on the valuation assumptions; it is not a predicted price move.
Explore the modelsRevenue
Dec 2025 vs Dec 2024
Reported revenue: ₹73 CrNet profit
Dec 2025 vs Dec 2024
Reported net profit: ₹11 CrProfit into cash
Operating cash flow / net profit
Matched annual period: Mar 2025₹1.00 of operating cash for each ₹1 of reported profit.
Latest-quarter profit fell 65.6% year on year; profit across the last four reported quarters fell 19.2%. Read the latest quarter alongside the longer trend.
Reporting dates, coverage & sources
Annual: Mar 2025 · Quarterly: Dec 2025 · Cash flow: Mar 2026. These sections refresh independently. A recent price update does not mean the financial statements are current.
Sources: Company data source. Check the company filings linked by the source for the reporting basis and exceptional items.
What the numbers reveal
See how growth, cash and financing fit together. Open any measure for its interpretation and source.
Quarterly net margin
-28.17 pp year on year
Dec 2025 vs Dec 2024Why it matters & source
Each ₹100 of revenue produced ₹15.07 of reported net profit. Compare the change with tax and other-income movements.
Net profit ÷ revenue × 100. Change is in percentage points (pp), not percent growth.
Current: ₹11.00 Cr profit / ₹73.00 Cr revenue. Prior: ₹32.00 Cr / ₹74.00 Cr.
View source tableRevenue momentum gap
Latest quarter -1.4% · trailing year +11.5%
Eight consecutive quarters ending Dec 2025Why it matters & source
The latest quarter grew more slowly than the four-quarter trend. This comparison describes momentum; it does not predict the next quarter.
Latest-quarter revenue YoY growth minus revenue growth of the latest four quarters against the preceding four.
Latest quarter: ₹73.00 Cr vs ₹74.00 Cr. Four-quarter totals: ₹282.00 Cr vs ₹253.00 Cr.
View source tableThree-year cash backing
Operating cash / reported profit
Mar 2023–Mar 2025 · 3 matched yearsWhy it matters & source
For every ₹1 of reported profit, the business generated ₹1.32 of operating cash across the matched years. Working capital, taxes and non-cash items can explain a gap.
Sum of operating cash flow ÷ sum of net profit over three consecutive, matching annual periods. This is not an average of yearly ratios.
Operating cash: ₹137.00 Cr. Net profit: ₹104.00 Cr.
View source tableInterest coverage
Earnings before interest and tax / interest
Mar 2025 · annual P&LWhy it matters & source
Reported earnings before interest and tax cover the interest expense 71.0 times. Other income is included; principal repayments are not.
(Profit before tax + interest expense) ÷ interest expense.
Profit before tax: ₹70.00 Cr. Interest: ₹1.00 Cr.
View source tableBorrowings / book equity
₹2.90 borrowed per ₹100 of equity
Mar 2026 · balance sheetWhy it matters & source
This compares reported borrowings with equity capital plus reserves. It is gross borrowing, not net debt; reserves are not cash.
Borrowings ÷ (equity capital + reserves), from the same balance-sheet date.
Borrowings: ₹8.00 Cr. Equity capital: ₹13.00 Cr. Reserves: ₹263.00 Cr.
View source tableCash cycle change
39 days now · 52 days before
Mar 2025 vs Mar 2024Why it matters & source
A shorter cycle can reduce the time cash is tied up in operations. A longer supplier-payment period can also shorten it, so read the components.
Cash cycle = debtor days + inventory days − payable days. Change = current cycle − prior-year cycle.
Current: 18 + 58 − 37 days. Prior: 19 + 68 − 35 days.
View source tableWhat growth does this price require?Change the assumptions and see the earnings hurdle
Start with the stored P/E of 34.00×. If the future P/E is lower, earnings must work harder to deliver the same price return.
For a 10% annual price return over 5 years at a future P/E of 25.50×.
Defaults illustrate a 25% fall in P/E, 10% annual price return and five years. They are assumptions, not forecasts. This is EPS growth, not total-profit growth; changes in share count matter. Dividends, taxes and costs are excluded.
Formula & data basis
Required growth = (1 + annual price return) × (current P/E ÷ future P/E)1 / years − 1. Returns and growth use decimals in this formula.
Uses the stored P/E and its underlying earnings basis, which may differ from the dated financial tables. Quote record: 26 September 2026, 6:29 am +05:30.
Periods are matched within each calculation; different measures may use different reporting dates. Derived from the stored tables, not live filings. Check the source reporting basis before comparing companies. About ratio analysis.
Valuation models
P/E (34.0) × ROE (17.3%) × BV (₹41.20) × 0.8 × (1 + dividend yield 1.65%)
Compare model estimates & weights
| Model | Category | Value | Weight | Signal |
|---|---|---|---|---|
| PE-ROE | Earnings | ₹229.28 | 21% | Fair (-5.3%) |
| Graham Number | Earnings | ₹75.44 | 15% | Over (-68.8%) |
| Earnings Power | Earnings | ₹37.70 | 10% | Over (-84.4%) |
| DCF | Cash Flow | ₹131.29 | 10% | Over (-45.7%) |
| Net Asset Value | Assets | ₹41.80 | 7% | Over (-82.7%) |
| EV/EBITDA | Enterprise | ₹70.27 | 8% | Over (-71%) |
| Dividend Discount | Dividends | ₹55.00 | 8% | Over (-77.3%) |
| Earnings Yield | Earnings | ₹61.40 | 7% | Over (-74.6%) |
| ROCE Capital | Returns | ₹66.45 | 8% | Over (-72.5%) |
| Revenue Multiple | Revenue | ₹40.74 | 5% | Over (-83.2%) |
| Consensus (10 models) | ₹101.72 | 100% | Overvalued | |
PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 16.3%
Margin of safety = (model value − price) ÷ model value. The agreement score is a heuristic based on model count, direction and spread; it is not a probability of accuracy. These models are estimates, not price targets.
Estimates depend on assumptions. Compare the model range and verify fresh filings.
Analysis summary
Data coverage: Price-data record updated 26 September 2026, 6:29 am +05:30. Annual results through Mar 2025; quarterly results through Dec 2025; cash flow through Mar 2026. Each section can have a different reporting period. The share price is not live.
Valuation in context
Jagsonpal Pharmaceuticals Ltd: the stored intrinsic value estimate is ₹101.72, compared with a stored share price of ₹242.00. The model value is 58.0% below that quote. The model classifies this as overvalued; it is an estimate dependent on the inputs and assumptions, not a price target or a buy/sell recommendation.
Operating performance
Revenue for Mar 2025 was ₹269.00 Cr, versus ₹209.00 Cr in Mar 2024 (28.7% year on year). Net profit for Mar 2025 was ₹55.00 Cr, versus ₹22.00 Cr in Mar 2024 (150.0% year on year). These are the latest annual periods stored on this page; check the quarterly table separately for more recent developments.
Cash generation
For the same Mar 2025 period, operating cash flow was ₹55.00 Cr against net profit of ₹55.00 Cr. Cash flow covered 1.00 times reported profit. Cash generation supports the reported profit for this period; check whether this continues over several years.
Balance-sheet check
Reported borrowings were ₹8.00 Cr in Mar 2026. Read this alongside cash, interest costs and repayment obligations; reserves are an accounting balance and are not the same as available cash.
How to use the valuation and peer comparisons
The Intrinsic Value panel combines the available model estimates using the displayed weights. Earnings, cash-flow, dividend and asset-based methods can give very different answers. The displayed 12% cost of equity and 4% terminal growth assumptions apply where relevant; historical EPS growth is not a promise of future growth. Use the individual values and their spread to judge sensitivity.
The peer group follows the stored industry classification and may include different business models. Compare reporting periods, leverage and recurring earnings before interpreting a valuation gap. For banks and other financial businesses, capital adequacy and asset quality can be more informative than industrial-company cash-flow ratios.
Sources: Company data source. Check the company filings linked by the source for the reporting basis and exceptional items.
Automatically generated interpretation of the stored financial data, not a separately researched analyst opinion. Missing data is not evidence of poor performance. New filings become available here after the existing data refresh process captures them.
Business quality
Data coverage: 5/5 dimensions. Financial reporting periods vary by section.
Open a dimension to see what drives its score. Stored ratio feeds and reporting dates can differ from the matched financial-statement calculations in Connect the numbers.
Stock Health91/100 · Strong
Profitability, balance sheet strength, debt levels, profit consistency
Ownership Trends70/100 · Strong
FII/DII trends, promoter changes, shareholder count shifts
Earnings Quality85/100 · Strong
Cash flow vs reported profit, margin trends, working capital efficiency
Quarterly Momentum50/100 · Moderate
Recent 4-quarter revenue and profit growth vs prior year
Peer Comparison60/100 · Moderate
P/E, ROCE, ROE, and growth vs industry averages
How the quality score is calculated
Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Peer Comparison 15% · Ownership Trends 10%. Scores use stored reporting periods and are screening indicators, not investment recommendations. Missing dimensions are excluded and the remaining weights are rescaled. At least three dimensions are required for an overall score. Holding movements describe ownership shares, not proven trading flows. Broad industry groups and financial-sector accounting can limit comparability.
Share price & basic dataAll stored headline metrics · Expand table
Share Price and Basic Stock Data
Last Updated: September 26, 2026, 6:29 am
| PEG Ratio | 2.08 |
|---|
Understand these figures: how to read the P/E ratio, ROE versus earnings per share, and calculate intrinsic value.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Jagsonpal Pharmaceuticals Ltd | 1,598 Cr. | 242 | 265/155 | 34.0 | 41.2 | 1.65 % | 22.7 % | 17.3 % | 2.00 |
| Amrutanjan Health Care Ltd | 1,464 Cr. | 506 | 760/476 | 23.5 | 128 | 0.97 % | 24.8 % | 18.4 % | 1.00 |
| TTK Healthcare Ltd | 1,457 Cr. | 1,031 | 1,250/735 | 19.0 | 789 | 0.97 % | 8.04 % | 6.30 % | 10.0 |
| Fermenta Biotech Ltd | 1,379 Cr. | 468 | 580/249 | 25.2 | 138 | 0.80 % | 20.6 % | 16.4 % | 5.00 |
| Kopran Ltd | 1,375 Cr. | 285 | 288/107 | 55.0 | 110 | 1.05 % | 6.65 % | 4.91 % | 10.0 |
| Industry Average | 23,045.10 Cr | 1,276.48 | 56.80 | 211.60 | 0.38% | 26.16% | 16.59% | 6.06 |
Quarterly resultsRevenue, profit and margins by quarter · Expand table
Quarterly Result
| Metric | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 60 | 55 | 60 | 58 | 47 | 43 | 61 | 75 | 74 | 59 | 76 | 74 | 73 |
| Expenses | 52 | 50 | 52 | 49 | 44 | 41 | 51 | 58 | 58 | 50 | 61 | 58 | 57 |
| Operating Profit | 9 | 5 | 9 | 8 | 3 | 3 | 10 | 16 | 16 | 9 | 14 | 16 | 16 |
| OPM % | 14% | 10% | 14% | 14% | 7% | 6% | 17% | 22% | 21% | 15% | 19% | 22% | 22% |
| Other Income | 2 | 3 | 2 | 2 | 3 | 2 | -2 | 2 | 26 | 3 | 3 | 3 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | 10 | 7 | 10 | 10 | 5 | 5 | 7 | 15 | 39 | 9 | 14 | 17 | 15 |
| Tax % | 21% | 24% | 26% | 25% | 25% | 22% | 25% | 25% | 17% | 24% | 25% | 25% | 25% |
| Net Profit | 8 | 6 | 7 | 7 | 4 | 4 | 5 | 11 | 32 | 7 | 11 | 13 | 11 |
| EPS in Rs | 1.19 | 0.85 | 1.14 | 1.14 | 0.60 | 0.54 | 0.81 | 1.73 | 4.82 | 0.99 | 1.62 | 1.89 | 1.64 |
Last Updated: February 5, 2026, 11:09 am
Annual profit & lossYearly operating and earnings history · Expand table
Profit & Loss - Annual Report
Last Updated: February 24, 2026, 3:16 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 144 | 138 | 143 | 144 | 127 | 167 | 159 | 188 | 218 | 237 | 209 | 269 | 282 |
| Expenses | 133 | 129 | 132 | 138 | 138 | 157 | 150 | 169 | 192 | 203 | 186 | 218 | 226 |
| Operating Profit | 11 | 9 | 12 | 6 | -11 | 9 | 9 | 19 | 26 | 34 | 23 | 51 | 56 |
| OPM % | 7% | 6% | 8% | 4% | -9% | 6% | 5% | 10% | 12% | 14% | 11% | 19% | 20% |
| Other Income | 0 | 0 | 1 | 13 | 0 | 1 | 3 | 4 | 3 | 2 | 9 | 28 | 9 |
| Interest | 5 | 4 | 5 | 3 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 3 | 3 | 3 | 2 | 0 | 1 | 1 | 1 | 2 | 1 | 2 | 8 | 9 |
| Profit before tax | 3 | 2 | 4 | 14 | -12 | 9 | 9 | 22 | 27 | 35 | 30 | 70 | 54 |
| Tax % | 16% | 30% | 20% | 18% | -1% | 20% | 16% | 22% | 29% | 23% | 25% | 21% | |
| Net Profit | 2 | 1 | 3 | 12 | -12 | 7 | 8 | 17 | 19 | 27 | 22 | 55 | 41 |
| EPS in Rs | 0.32 | 0.18 | 0.50 | 1.81 | -1.76 | 1.10 | 1.20 | 2.60 | 2.88 | 4.08 | 3.40 | 8.34 | 6.14 |
| Dividend Payout % | 62% | 22% | 8% | 2% | -2% | 9% | 17% | 15% | 56% | 49% | 59% | 30% |
Growth
Last Updated: September 5, 2025, 8:00 am
Balance sheetAssets, equity and borrowings · Expand table
Balance Sheet
Last Updated: September 10, 2026, 4:00 am
| Month | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
| Reserves | 82 | 85 | 97 | 85 | 91 | 98 | 109 | 120 | 146 | 174 | 227 | 263 |
| Borrowings | 39 | 38 | 8 | 8 | 4 | 5 | 7 | -0 | 6 | 9 | 9 | 8 |
| Other Liabilities | 19 | 22 | 25 | 23 | 28 | 31 | 35 | 31 | 30 | 21 | 29 | 32 |
| Total Liabilities | 154 | 159 | 143 | 130 | 136 | 147 | 164 | 164 | 195 | 217 | 278 | 317 |
| Fixed Assets | 52 | 52 | 22 | 21 | 22 | 22 | 26 | 23 | 24 | 9 | 94 | 85 |
| CWIP | -0 | -0 | -0 | 3 | 4 | 4 | -0 | -0 | -0 | -0 | -0 | -0 |
| Investments | -0 | -0 | -0 | -0 | -0 | 11 | 15 | 51 | 1 | -0 | -0 | -0 |
| Other Assets | 102 | 108 | 121 | 105 | 110 | 109 | 123 | 91 | 170 | 208 | 184 | 231 |
| Total Assets | 154 | 159 | 143 | 130 | 136 | 147 | 164 | 164 | 195 | 217 | 278 | 317 |
Cash flow statementOperating, investing and financing flows · Expand table
Cash Flow
| Month | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free cash flowCash remaining after capital expenditure · Expand table
Free Cash Flow
| Period | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 4.00 | 6.00 | 40.00 | -5.00 | 30.00 | 12.00 | 28.00 | 6.00 | 48.00 | 35.00 | 90.00 | 47.00 |
This table and the chart use the Free Cash Flow row from the same stored cash-flow statement. Free cash flow generally measures operating cash flow after capital expenditure; check the source definition and reporting basis. It is not operating profit minus borrowings.
Financial efficiencyWorking-capital and operating-cycle measures · Expand table
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 115 | 119 | 106 | 100 | 73 | 45 | 49 | 25 | 26 | 32 | 19 | 18 |
| Inventory Days | 173 | 176 | 246 | 295 | 307 | 164 | 191 | 134 | 122 | 82 | 68 | 58 |
| Days Payable | 29 | 42 | 60 | 56 | 54 | 59 | 76 | 82 | 76 | 66 | 35 | 37 |
| Cash Conversion Cycle | 259 | 252 | 292 | 339 | 325 | 150 | 164 | 77 | 72 | 48 | 53 | 39 |
| Working Capital Days | 64 | 68 | 72 | 154 | 149 | 67 | 55 | 32 | 59 | 34 | 52 | 9 |
| ROCE % | 6% | 5% | 7% | 3% | -10% | 9% | 9% | 18% | 20% | 25% | 17% | 23% |
Shareholding patternOwnership shares across reporting dates · Expand table
Mutual fund holdingsReported fund ownership · Expand table
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF | 83 | 0.04 | 0 | 83 | 2025-04-22 17:25:30 | 0% |
Key financial ratiosAlternate ratio feed and dated comparisons · Expand table
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Basic EPS (Rs.) | 8.26 | 8.49 | 10.20 | 7.48 | 6.51 |
| Diluted EPS (Rs.) | 8.22 | 8.46 | 10.20 | 7.48 | 6.51 |
| Cash EPS (Rs.) | 9.56 | 9.13 | 10.66 | 8.06 | 6.71 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 36.08 | 70.88 | 60.65 | 46.96 | 43.55 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 36.08 | 70.88 | 60.65 | 49.95 | 46.54 |
| Dividend / Share (Rs.) | 2.50 | 5.00 | 5.00 | 4.00 | 1.00 |
| Revenue From Operations / Share (Rs.) | 40.47 | 78.94 | 90.36 | 86.30 | 71.74 |
| PBDIT / Share (Rs.) | 8.92 | 12.23 | 15.22 | 11.12 | 8.96 |
| PBIT / Share (Rs.) | 7.70 | 11.61 | 14.76 | 10.54 | 8.76 |
| PBT / Share (Rs.) | 10.52 | 11.30 | 13.29 | 10.43 | 8.35 |
| Net Profit / Share (Rs.) | 8.34 | 8.50 | 10.20 | 7.48 | 6.51 |
| PBDIT Margin (%) | 22.05 | 15.49 | 16.84 | 12.88 | 12.48 |
| PBIT Margin (%) | 19.02 | 14.70 | 16.34 | 12.20 | 12.21 |
| PBT Margin (%) | 25.99 | 14.31 | 14.70 | 12.08 | 11.63 |
| Net Profit Margin (%) | 20.60 | 10.76 | 11.28 | 8.66 | 9.07 |
| Return on Networth / Equity (%) | 23.11 | 11.98 | 16.81 | 15.92 | 14.95 |
| Return on Capital Employeed (%) | 20.26 | 15.50 | 23.10 | 20.55 | 18.54 |
| Return On Assets (%) | 19.89 | 10.34 | 13.70 | 11.62 | 10.38 |
| Total Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 |
| Asset Turnover Ratio (%) | 1.08 | 1.01 | 1.30 | 1.36 | 1.21 |
| Current Ratio (X) | 6.22 | 10.42 | 5.97 | 3.24 | 2.98 |
| Quick Ratio (X) | 5.64 | 9.63 | 5.22 | 2.37 | 2.25 |
| Inventory Turnover Ratio (X) | 17.80 | 1.24 | 1.24 | 1.36 | 1.31 |
| Dividend Payout Ratio (NP) (%) | 23.89 | 58.31 | 0.00 | 53.50 | 15.35 |
| Dividend Payout Ratio (CP) (%) | 20.83 | 54.29 | 0.00 | 49.63 | 14.91 |
| Earning Retention Ratio (%) | 76.11 | 41.69 | 0.00 | 46.50 | 84.65 |
| Cash Earning Retention Ratio (%) | 79.17 | 45.71 | 0.00 | 50.37 | 85.09 |
| Interest Coverage Ratio (X) | 61.86 | 39.74 | 96.57 | 102.18 | 21.61 |
| Interest Coverage Ratio (Post Tax) (X) | 38.24 | 28.60 | 74.08 | 69.70 | 16.71 |
| Enterprise Value (Cr.) | 1305.18 | 591.93 | 644.85 | 795.42 | 154.96 |
| EV / Net Operating Revenue (X) | 4.86 | 2.84 | 2.72 | 3.52 | 0.82 |
| EV / EBITDA (X) | 22.02 | 18.30 | 16.17 | 27.31 | 6.60 |
| MarketCap / Net Operating Revenue (X) | 5.34 | 3.54 | 3.21 | 3.63 | 1.11 |
| Retention Ratios (%) | 76.10 | 41.68 | 0.00 | 46.49 | 84.64 |
| Price / BV (X) | 5.99 | 3.95 | 4.78 | 6.68 | 1.83 |
| Price / Net Operating Revenue (X) | 5.34 | 3.54 | 3.21 | 3.63 | 1.11 |
| EarningsYield | 0.03 | 0.03 | 0.03 | 0.02 | 0.08 |
Frequently asked questions
What is the intrinsic value of Jagsonpal Pharmaceuticals Ltd and is it undervalued?
Jagsonpal Pharmaceuticals Ltd: the stored intrinsic value estimate is ₹101.72, compared with a stored share price of ₹242.00. The model value is 58.0% below that quote. The model classifies this as overvalued; it is an estimate dependent on the inputs and assumptions, not a price target or a buy/sell recommendation. The estimate uses the available valuation models and weights shown in the Intrinsic Value panel, including earnings, cash-flow and asset-based approaches where data permits. It is not a P/E-only calculation.
What share price and 52-week range are shown for Jagsonpal Pharmaceuticals Ltd?
The stored share price is ₹242.00. Price-data record updated: 26 September 2026, 6:29 am +05:30. This is not a live quote. The stored 52-week high / low is 265/155; this is a rolling range, not a financial-year range.
How have Jagsonpal Pharmaceuticals Ltd's revenue and profit changed?
Revenue for Mar 2025 was ₹269.00 Cr, versus ₹209.00 Cr in Mar 2024 (28.7% year on year). Net profit for Mar 2025 was ₹55.00 Cr, versus ₹22.00 Cr in Mar 2024 (150.0% year on year). These are the latest annual periods stored on this page; check the quarterly table separately for more recent developments.
Does Jagsonpal Pharmaceuticals Ltd's profit convert into cash?
For the same Mar 2025 period, operating cash flow was ₹55.00 Cr against net profit of ₹55.00 Cr. Cash flow covered 1.00 times reported profit. Cash generation supports the reported profit for this period; check whether this continues over several years.
What should I check in Jagsonpal Pharmaceuticals Ltd's balance sheet?
Reported borrowings were ₹8.00 Cr in Mar 2026. Read this alongside cash, interest costs and repayment obligations; reserves are an accounting balance and are not the same as available cash.
How should I compare Jagsonpal Pharmaceuticals Ltd's P/E with other stocks?
The stored P/E is 34.00. Compare companies with similar business models, growth, leverage and accounting periods. The industry group on this page is broad, and its average can be affected by outliers. A lower P/E alone does not establish undervaluation.
What could change Jagsonpal Pharmaceuticals Ltd's intrinsic value estimate?
Changes in sustainable earnings, cash generation, capital needs, debt and share count can change the estimate. The displayed model uses a 12% cost of equity and 4% terminal growth assumption where applicable. Higher discount rates or weaker growth generally reduce discounted values. Compare the individual model values and weights, and verify fresh filings before relying on the result.